Company news

XOMA Royalty Corporation news in 2024

XOMA Royalty Corporation's news releases, calls and decks from 2024, newest first.

View company

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

December 1, 2024

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

November 6, 2024

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

August 12, 2024

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

May 8, 2024

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

April 24, 2024

XOMA Corporation Announces Closing of Tender Offer

April 2, 2024

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

March 18, 2024

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

March 7, 2024

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

February 15, 2024

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

January 17, 2024

XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

January 7, 2024

XOMA Announces Stock Repurchase Program of up to $50 Million

January 1, 2024

Decks in 2024